Clinical Trial Update: Exploratory Study of SPD489 in Adults With Major Depressive Disorder (MDD) as Augmentation Therapy to an Antidepressant [Phase 2]

View source ↗

Summary

Phase 2 exploratory study of SPD489 as augmentation to antidepressant in adults with major depressive disorder has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Major Depressive Disorder

Drugs mentioned

• SPD489

Snippet

Sponsor: Shire | Conditions: Major Depressive Disorder | Phase 2 | Status: COMPLETED | Results posted: 2011-07-14